Glioblastoma, which kills roughly Americans each year, remains challenging to treat. The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray activated modality for drug delivery to treat glioblastoma. GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a […]
Immunotherapy
Orum Therapeutics raises $84M for targeted protein degrader payloads
Orum Therapeutics announced today that it closed an $84 million Series B financing for its targeted protein degraders for treating cancer. Boston-based Orum’s funding round includes a previously announced $30 million financing, plus another $54 million in new funds led by IMM Investment and joined by new investors KDB Investment and Atinum, among others. Existing […]
Interius BioTherapeutics raises $76M Series A
Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generates chimeric antigen receptor (CAR) T cells directly in vivo to bypass the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required […]
FDA accepts IND application for Samus Therapeutics’ oral glioma drug
Samus Therapeutics announced today that the FDA cleared its investigational new drug (IND) application for its glioma treatment. Boston-based Samus Therapeutics develops the PU-AD (icapamespib) orally administered small molecule drug for the treatment of recurrent malignant glioma, according to a news release. Under the IND, Samus will move forward with its Phase 1b study to […]
Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides’ Port study is an open-label, randomized, crossover study comparing the safety, tolerability and efficacy of peripheral or central intravenous administration of Pepaxto (melphalan flufenamide) in combination with dexamethasone to treat relapsed refractory multiple […]
D&D Pharmatech to collaborate with Yale on brain cancer therapies
D&D Pharmatec announced today that it is collaborating with Yale to optimize two approaches to treating brain cancer and other disorders. The sponsored research agreement is slated to work with two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier (BBB) when treating brain cancer, among other diseases, according […]
Terumo launches therapeutic interventional oncology team
Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]
TriSalus, University of Texas to collaborate on solid tumor treatment study
TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]
UroGen Pharma raises $75M
UroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million. Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal […]
Bicara Therapeutics launches with $40M investment
Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]
